Bristol-Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application of Opdivo (nivolumab), which seeks to extend Opdivo’s current indications to include the treatment of classical Hodgkin’s lymphoma (cHL) patients after prior therapies. The ... Read more